Clinical use of cardiac 18 F-FDG viability PET: a retrospective study of 44 patients undergoing post-test revascularization.
Thien Vinh LuongAndreas EbbehojMette Louise Gram KjaerulffRoni NielsenPer Hostrup NielsenEvald Høj ChristiansenLars Poulsen TolbodEsben SøndergaardLars Christian GormsenPublished in: The international journal of cardiovascular imaging (2022)
The coupling between coronary artery disease and the development of ischemic heart failure is well-established. For these patients, assessment of potentially viable but dysfunctional myocardial tissue (hibernation) is considered critical to guide optimal surgical treatment. Assessment with positron emission tomography (PET) theoretically provides measurements of hibernating tissue and maximal myocardial glucose uptake (MGU) in all cardiac territories. However, the clinical benefits of these measures are not thoroughly studied. We therefore aimed to investigate whether cardiac viability testing with combined Rubidium-82 ( 82 Rb) and 18 F-fluorodeoxyglucose ( 18 F-FDG) predicts post-intervention improvement in left ventricle ejection fraction (LVEF) and survival. This retrospective study consisted of 131 patients with ischemic heart failure referred for dynamic 82 Rb/ 18 F-FDG PET viability testing prior to revascularization. The FDG viability scan was done during a hyperinsulinemic-euglycemic clamp and included PET measures static FDG hibernation and absolute MGU as well as myocardial blood flow and coronary flow reserve. In total, 44/131 patients undergoing viability testing were subsequently revascularized. Following revascularization, 26 patients had LVEF improvement of at least 5% while 18 patients had no improvement. A poor correlation between areas of intervention and areas of hibernation was observed. Receiver operating characteristics for all PET metrics did not predict improvement in LVEF. Furthermore, hibernation failed to predict survival regardless of whether patients underwent subsequent revascularization. Dynamic viability PET metrics (hibernation and MGU) do not predict post-intervention improvement in LVEF or overall survival in ischemic heart failure patients undergoing revascularization. In a clinical setting, the value of these measurements may therefore be limited. Kindly check and confirm the Given names and Family names for all the authors.All names are correct!
Keyphrases
- positron emission tomography
- ejection fraction
- computed tomography
- pet ct
- heart failure
- pet imaging
- end stage renal disease
- patients undergoing
- left ventricular
- coronary artery disease
- chronic kidney disease
- newly diagnosed
- aortic stenosis
- randomized controlled trial
- prognostic factors
- blood flow
- peritoneal dialysis
- coronary artery bypass grafting
- metabolic syndrome
- adipose tissue
- insulin resistance
- magnetic resonance imaging
- blood pressure
- mitral valve
- skeletal muscle
- pulmonary hypertension
- acute coronary syndrome
- room temperature
- free survival
- resistance training
- pulmonary arterial hypertension
- high intensity
- glycemic control
- clinical evaluation